Global Golidocitinib Market Strategic Research Report

Scope of the Report

The global Golidocitinib market size is predicted to grow from US$ 221 million in 2025 to US$ 970 million in 2032; it is expected to grow at a CAGR of 17.3% from 2026 to 2032.

Golidocitinib is a highly selective, orally bioavailable small-molecule JAK1 inhibitor, mainly used for the treatment of hematologic malignancies such as relapsed or refractory peripheral T-cell lymphoma. The drug specifically inhibits the JAK-STAT signaling pathway, blocking abnormal cell proliferation and inflammatory signal transduction, thereby suppressing tumor cell growth and delaying disease progression. As a new generation of targeted antineoplastic agents, golidocitinib features high target selectivity, low off-target effects, and controllable clinical safety. It provides a new therapeutic option for patients with relapsed and refractory lymphoma and represents one of the important innovative targeted drugs in the field of lymphoma.In 2025, global Golidocitinib production reached approximately 110,000–120,000 bottles.

As a globally first-in-class highly selective JAK1 inhibitor, golidocitinib has precisely filled the long-standing clinical gap in the treatment of relapsed and refractory peripheral T-cell lymphoma since its launch. With its unique mechanism of action and significant survival benefits, it has rapidly established a core position in the targeted market. Relying on its globally exclusive target, breakthrough therapeutic efficacy, and highest-level recommendations from authoritative clinical guidelines, the drug has built strong market competitiveness and technical barriers. Following its inclusion in medical insurance, its accessibility has been greatly improved, market penetration and patient coverage continue to expand, and the commercialization process has accelerated significantly. In terms of competitive landscape, it enjoys obvious first-mover advantages, while similar competitors remain in late-stage clinical development, making it difficult to challenge its dominant position in the short term. Meanwhile, with the active expansion of multiple indications such as first-line treatment, combination therapy, and other T-cell lymphoma subtypes, golidocitinib is extending from second-line salvage therapy to full-course disease management, continuously unlocking its market potential and product life cycle. In the future, it is expected to further consolidate its benchmark value in the global targeted therapy for hematologic malignancies through its differentiated advantages and international layout.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Golidocitinib market?

What factors are driving Golidocitinib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Golidocitinib market opportunities vary by end market size?

How does Golidocitinib break out by Type, by Application?

This report presents a comprehensive overview of the global Golidocitinib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 150 mg
• 100 mg

Segment by Application

• Relapsed Or Refractory Peripheral T-Cell Lymphoma
• Other T-Cell Lymphoma Subtypes
• Hematologic Malignancies
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Golidocitinib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Relapsed Or Refractory Peripheral T-Cell Lymphoma, Other T-Cell Lymphoma Subtypes, Hematologic Malignancies evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact